Predictors of Response to Conventional Dmards In Rheumatoid Arthritis Patients Presenting In A Tertiary Care Hospital of Pakistan

Saira  Yasmin; Umm E Laila  Hashmi; Maryam  Ahmed; Maimona  Firdus; Shahida  Perveen; Babur  Salim

doi:10.51253/pafmj.v76iSUPPL-2.12842

Authors

Saira Yasmin Department of Rheumatology, Fauji Foundation Hospital Rawalpindi Pakistan
Umm E Laila Hashmi Department of Rheumatology, Fauji Foundation Hospital Rawalpindi Pakistan
Maryam Ahmed Department of Rheumatology, Fauji Foundation Hospital Rawalpindi Pakistan
Maimona Firdus Department of Rheumatology, Fauji Foundation Hospital Rawalpindi Pakistan
Shahida Perveen Department of Rheumatology, Fauji Foundation Hospital Rawalpindi Pakistan
Babur Salim Department of Rheumatology, Fauji Foundation Hospital Rawalpindi Pakistan

DOI:

https://doi.org/10.51253/pafmj.v76iSUPPL-2.12842

Keywords:

Body Mass Index, Disease modifying anti-rheumatic drugs, Rheumatoid arthritis, Serology

Abstract

Objective: Conventional disease modifying anti-rheumatic drugs (DMARDs) are the first line drugs in a conventional DMARDs in Pakistan.

Study Design: Prospective cohort study.

Place and Duration of Study: Rheumatology Department of FFH Rawalpindi, Pakistan from Oct 2023 to Mar 2024.

Methodology: We included 224 cases of treatment naïve early Rheumatoid arthritis with moderate to high disease activity. Disease activity was assessed by DAS28 CRP. Baseline data were collected for demographic, clinical parameters and serology. Treatment response was categorized into good (DAS28 CRP≤3.2) and poor response (DAS28 CRP >3.2) at 3 months after treatment with conventional DMARDS. Predictors of treatment response were assessed by logistic regression analysis.

Results: Females constituted 196(87.5%) patients. 118(52.7%) patients were seropositive. At 3 months, 139(62.1%) achieved remission, 65(29%) low, and 20(8.9%) moderate disease activity. 204(91.1%) patients achieved good response. The response was dependent on baseline disease activity as measured in terms of change in DAS-28 CRP.

Conclusion: Patients with higher BMI has poorer response to conventional DMARDs. Weight optimization may be important step in improving the response to DMARDs in patients with Rheumatoid arthritis.

Downloads

Download data is not yet available.

References

1. Lee JE, Kim IJ, Cho MS, Lee J. A Case of Rheumatoid Vasculitis Involving Hepatic Artery in Early Rheumatoid Arthritis. J Korean Med Sci 2017; 32((7)): 1207–1210.

https://doi.org/10.3346/jkms.2017.32.7.1207

2. Fox CQ, Ahmed SS. Physician Assistant's Clinical Review Cards. Philadelphia: F. A. Davis Company; 2002. pp. 138–139.

3. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet 2016; 388: 2023–2038.

https://doi.org/10.1016/S0140-6736(16)30173-8

4. Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis: Pathological mechanisms and modern pharmacologic therapies. Bone Res 2018; 6(1): 1–15.

https://doi.org/10.1038/s41413-018-0016-9

5. Stoffer MA, Schoels MM, Smolen JS. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. Ann Rheum Dis 2016; 75: 16–22.

https://doi.org/10.1136/annrheumdis-2015-207526

6. Drosos AA, Pelechas E, Voulgari PV. Rheumatoid arthritis treatment. A back to the drawing board project or high expectations for low unmet needs? J Clin Med 2019; 8: 1237. https://doi.org/10.3390/jcm8081237

7. Bijlsma JW. Disease control with glucocorticoid therapy in rheumatoid arthritis. Rheumatology 2012; 51(Suppl4): iv9–iv13.

https:/doi.org/10.1093/rheumatology/kes086

8. Smolen JS, van Vollenhoven RF, Florentinus S, Chen S, Suboticki JL, Kavanaugh A. Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate. Ann Rheum Dis 2018; 77(11): 1566-1572.

https://doi.org/10.1136/annrheumdis-2018-213502

9. Teitsma XM, Jacobs JWG, Welsing PMJ. Inadequate response to treat-to-target methotrexate therapy in patients with newonset rheumatoid arthritis: development and validation of clinical predictors. Ann Rheum Dis 2018; 77(9): 1261-1267.

https://doi.org/10.1136/annrheumdis-2018-213035

10. Sergeant JC, Hyrich KL, Anderson J, et al. Prediction of primary nonresponse to methotrexate therapy using demographic, clinical and psychosocial variables: Results from the UK Rheumatoid Arthritis Medication Study (RAMS). Arthritis Res Ther 2018; 20(1): 1-11.

https://doi.org/10.1186/s13075-018-1645-5

11. Shinde CG, Venkatesh MP, Kumar TM, Shivakumar HG. Methotrexate: a gold standard for treatment of rheumatoid arthritis. J Pain Palliat Care Pharmacother 2014; 28(1): 351-358.

https://doi.org/ 10.3109/15360288.2014.959238

12. Mucke J, Brinks R, Dimitriou A, Richter JG, Schneider M. Treatment expectations as a possible prognostic factor for DMARD response in rheumatoid arthritis: a prospective cohort study. Ther Advan Musculoskel Dis 2021; 13.

https://doi.org/10.1177/1759720X211015829

13. Kaltsonoudis E, Pelechas E, Voulgari PV. Unmet needs in the treatment of rheumatoid arthritis. An observational study and a real-life experience from a single university center. Semin Arthritis Rheum 2019; 48: 597–602. https://doi.org/10.1016/j.semarthrit.2018.06.003

14. Ling S, Bluett J, Barton A. Prediction of response to methotrexate in rheumatoid arthritis. Exp Rev Clin Immunol 2018; 14(5): 419–429.

https://doi.org/ 10.1080/1744666X.2018.1465409

15. Dey M, Zhao SS, Robert J Moots RJ. The association between increased body mass index and response to conventional synthetic disease-modifying anti-rheumatic drug treatment in rheumatoid arthritis: results from the METEOR database. Rheumatology 2022 ; 61(2): 713–722.

https://doi.org/ 10.1093/rheumatology/keab389

16. Duong SQ, Crowson CS, Athreya A, Atkinson EJ, Davis JM 3rd, Warrington KJ, et al. Clinical predictors of response to methotrexate in patients with rheumatoid arthritis: a machine learning approach using clinical trial data. Arthritis Res Ther 2022; 24(1): 162.

https://doi.org/:10.1186/s13075-022-02851-5

17. Nikiphorou E, Norton S, Young A. The association of obesity with disease activity, functional ability and quality of life in early rheumatoid arthritis: data from the Early Rheumatoid Arthritis Study/Early Rheumatoid Arthritis Network UK prospective cohorts. Rheumatology2018; 57: 1194–202.

https://doi.org/ 10.1093/rheumatology/key066

18. Mori S, Okada A, Shimizu T, Takatani A, Koga T. Structural and Functional Outcomes in Rheumatoid Arthritis After 10-Year Therapy with Disease-Modifying Antirheumatic Drugs Under Tight Control: Evidence from Real-World Cohort Data. J Clin Med 2025; 14(19): 6832. https://doi.org/10.3390/jcm14196832